Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nura Bio

Explore full profile

Nura Bio™ | Developing neurotherapeutics to halt serious diseases before they progress too far

San Francisco, United StatesFounded 2018Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2026
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nura Bio and the history behind them.

About Nura Bio

Nura Bio is a pioneering company in the field of neuroprotective therapies, focusing on halting the progression of neurological diseases. The company targets fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity. Nura Bio serves patients affected by serious neurological conditions, offering renewed hope through innovative treatments. Operating in the biopharmaceutical market, Nura Bio's business model revolves around transforming recent scientific breakthroughs into effective neuroprotective medicines. Revenue is generated through the development and commercialization of these therapies. The company is led by a team of leading biologists, chemists, and drug developers, all united by a shared passion for revolutionizing the treatment of neurological diseases.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2018
Headquarters
San Francisco, United States
Employees
33
Open positions
3
Dealroom signal
50.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b
Links
WebsiteLinkedInX

Latest news

Press, funding announcements and product moves mentioning Nura Bio.

See all news

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jun 2026 $74M $295M Undisclosed ↗
SERIES AOther financing Sep 2024 $68M $272M Sanofi Ventures · Euclidean Capital · Samsara BioCapital · The Column Group ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Nura Bio website traffic

Latest recorded traffic for Nura Bio is 4K monthly website visits, up 66.7% over the last three months. Nura Bio's team grew 10% over the past year.

Latest monthly visits4K 3-month web change+66.7% 1-year team growth+10%
Monthly website visitsAug 2020–Jul 2026
Explore monthly traffic historyTrack growth over time and compare with peersBook a demo
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
Clinical Supply Chain ManagerSouth San Francisco, CA · Logistics · Aug 25, 2026
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
AzureCell TherapiesRegenerative cell therapies for neurodegenerative disorders Geneva, Switzerland Operational 4 — —
Atalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases Boston, United States Operational
Aspen NeuroscienceBiotechnology company that uses innovative genomic approaches combined with stem cell biology San Diego, United States Operational
AstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases Reading, United Kingdom Operational
Synendos TherapeuticsDeveloped first-in-class endocannabinoid modulators to restore natural functioning of the brain in CNS disorders Basel, Switzerland Operational
LocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA San Diego, United States Operational
Praxis Precision MedicinesDeveloping therapies for central nervous system disorders based on genetic insights into neuronal imbalance Cambridge, United States Operational
SwanBio TherapeuticsGene therapy company focused on the development and commercialisation of genetically defined therapies Lower Merion Township, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • The Column Group
  • Euclidean Capital
  • Samsara BioCapital
  • Sanofi Ventures

Other known investors2 additional known investors

  • Oregon Health & Science University
  • The University of Texas Southwestern Medical School

Talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nura Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nura Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.